13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $76M | -$17M | 0.0% | -29.3% | -$76M | — | $13M |
| 2024 | $138M | $32M | 0.0% | 18.1% | -$87M | — | $38M |
| 2023 | $101M | -$569000 | 0.0% | -6.4% | -$57M | — | $17M |
| 2022 | $53M | -$99M | 0.0% | -190.6% | -$113M | — | $194M |
| 2021 | $37M | -$116M | 0.0% | -311.0% | -$121M | — | $206M |
| 2020 | $68M | -$65M | 0.0% | -117.7% | $3M | — | $192M |
| 2019 | $27M | -$133M | 0.0% | -525.9% | -$144M | — | $188M |
| 2018 | $60M | -$85M | 0.0% | -130.9% | -$79M | — | $248M |
| 2017 | $72M | -$43M | 0.0% | -64.6% | $169M | — | $178M |
| 2016 | $13M | -$59M | 0.0% | -463.9% | -$4M | — | $105M |
| 2015 | — | -$35M | — | — | — | — | $60M |
| 2014 | — | -$30M | — | — | — | $3M | $64M |
| 2013 | — | -$15M | — | — | — | — | $9M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $10M | -$18M | 0.0% | -191.8% | -$26M | — | $29M |
| Dec '25 | $663000 | -$27M | 0.0% | -4213.0% | -$23M | — | $13M |
| Sep '25 | $6M | -$14M | 0.0% | -264.4% | -$15M | — | $34M |
| Jun '25 | $19M | -$154000 | 0.0% | -6.9% | -$16M | — | $49M |
| Mar '25 | $51M | $24M | 0.0% | 44.4% | -$21M | — | $48M |
| Dec '24 | $38M | $19M | 0.0% | 46.4% | -$20M | — | $38M |
| Sep '24 | $33M | $6M | 0.0% | 12.3% | -$21M | — | $41M |
| Jun '24 | $25M | -$7M | 0.0% | -33.7% | -$20M | — | $43M |
| Mar '24 | $41M | $14M | 0.0% | 28.1% | -$26M | — | $36M |
| Dec '23 | $27M | $837000 | 0.0% | -2.3% | -$22M | — | $17M |
| Sep '23 | $26M | $3M | 0.0% | 11.8% | -$18M | — | $26M |
| Jun '23 | $25M | -$1M | 0.0% | -13.5% | -$26M | — | $58M |
| Mar '23 | $23M | -$3M | 0.0% | -24.1% | $9M | — | $56M |
| Dec '22 | $20M | -$9M | 0.0% | -47.2% | -$2M | — | $194M |
| Sep '22 | $11M | -$29M | 0.0% | -266.5% | -$34M | — | $95M |
| Jun '22 | $13M | -$29M | 0.0% | -233.8% | -$35M | — | $129M |
| Mar '22 | $9M | -$32M | 0.0% | -354.7% | -$42M | — | $163M |
| Dec '21 | -$13M | -$58M | 0.0% | 467.3% | -$31M | — | $206M |
| Sep '21 | $18M | -$23M | 0.0% | -128.7% | -$30M | — | $236M |
| Jun '21 | $16M | -$19M | 0.0% | -117.9% | -$28M | — | $256M |
How the market has priced CTMX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cytomx Therapeutics, Inc.'s revenue has grown 2.2% per year. These are computed facts, not advice.
As of FY2025, Cytomx Therapeutics, Inc. reported — of total debt against $13M of cash.
In FY2025, gross margin was —, operating margin -29.3%, and net margin -22.8%.
As of Jun '26, Cytomx Therapeutics, Inc. traded at a price-to-earnings ratio of about 29.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.